expand_moreexpand_less
Aeon
Al Jazeera
América Economía
Blitz
Buenos Aires Herald
Deutsche Welle
Dnevnik
E-International
Haaretz
Il Manifesto Global
Japan Today
Khaama PressMiddle East MonitorNikkei Asian ReviewOped Column
Pravda.sk
Project Syndicate
Psychology Today
RT.comSME.sk
South China Morning PostThe Asahi ShimbunThe DiplomatThe Japan NewsThe Japan Times
The Korea TimesThe Times of IsraelThe Times of Israel (Blogs)Večer
العين الإخبارية 
Toi StaffEmanuel FabianJacob MagidAgenciesReuters
Gideon LevyThe Japan News EditorialLazar BermanGianluca PacchianiDavid Horovitz
Andrew Mitrovica
Somdeep SenJeremy SharonSam Sokol
Belen FernandezAmérica EconomíaJessica SteinbergRenee Ghert-ZandAndrew LapinCathryn J. PrinceSue SurkesLuke TressCanaan LidorNoa LandauAmy SpiroAmira HassZvi Bar&x27ElHanin MajadliMatt LebovicDavid RothkopfNatan OdenheimerYuli TamirThe Asahi ShimbunEran YashivGavriel Fiske
Ali Fathollah-NejadAmanda Borschel-DanEtan Nechin
Tafi MhakaMegan KangUri MisgavWilliam Noah GlucroftJames ShimanyulaAhmad IbsaisRon KampeasKate HairsineMartina JaureguyMichael Horovitz
Stephen OlsonAbbas Juma
|
|
Lynn ParramoreBusiness Insider |
Big Pharma is more focused on Wall Street games to enrich executives and shareholders than making medicines.
It will take a lot to address America’s extreme wealth concentration, but one ingredient is critical: tangible financial resources.
Since the majority of Americans want more revenue to strengthen it, why shouldn’t the small fraction of the highest-income Americans, especially the...
login
who are we?
contact us
qosheapp
